Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 499-503

  Desai, Dhimant ^a   Das, Arunangshu ^a   Cohen, Leonard ^a   El Bayoumy, Karam ^a   Amin, Shantu ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Chemoprevention; Lung tumor; Mice; Suberoylanilide hydroxamic acid

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HYDROXYLATION; LIVER MICROSOME; LUNG CANCER; LUNG CARCINOGENESIS; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENS; FEMALE; HYDROXAMIC ACIDS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED A; MICROSOMES; MICROSOMES, LIVER; NITROSAMINES;

EID: 0037236445     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind R and Marks P: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93: 5705-5708, 1996.
2. Breslow R, Marks P, Rifkind R and Jursic B: Novel potent inducers of terminal differentiation and methods of use thereof. PCT Int. Appl. WO 93/07148, 15 April, 1993, Chem Abstr 119: 138765k, 1993.
3. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D and Richon VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 19: 4999-5006, 1999.
4. Cohen LA, Marks, PA, Rifkind RA, Amin S, Desai D and Richon V: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22: 1497-1504, 2002.
5. Munster PN, Toroso-Sandoval T, Rosen N, Rifkind R, Marks PA and Richon V: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497, 2001.
6. Richon VM and O'Brian JP: Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res 8: 662-664, 2002.
7. Said TK, Moraes RCB, Sinha R and Medina D: Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res 14: 169-178, 2001.
8. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and downregulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705, 2002.
9. Hecht SS: Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Environ Health Perspect 105: 955-963, 1997.
10. Hecht SS: Biochemistry, biology and carcinogenicity of tobaccospecific N-nitrosamines. Invited review. Chem Res Toxicol 11: 559-603, 1998.
11. Stowell J, Huot R and VanSoast L-J: The synthesis of N-hydroxy-N′-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. J Med Chem 38: 1411-1413, 1995.
12. 3H)SAHA), a potent cytodifferentiating agent. J Labelled Cpd Radiopharm 43: 229-336, 2000.
13. Hecht SS, Morse MA, Amin S, Stoner GD, Jordan K, Choi C-I and Chung F-L: Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 10: 1901-1904, 1989.
14. El-Bayoumy K and Hoffmann D: Nutrition and tobacco-related cancer, Chapter 20. In: Nutritional Oncology (Heber D and Blackburn G, eds). Academic Press, San Diego, CA 1999, pp 299-324.
15. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
16. Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.